Results 41 to 50 of about 354,756 (297)

Oral Anticoagulants in Women: What's the Difference? A Narrative Review

Clinical and Applied Thrombosis/Hemostasis
Gender sensitive medicine refers to the need to individualize epidemiology, diagnosis, knowledge of disease presentation, and therapy based also on sex and gender. An impressive amount of scientific literature deals now with sex and gender differences in
Elena Maria Faioni M.D, Barbara Scimeca M.D   +1 more
doaj   +1 more source

Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab in vitro

Research and Practice in Thrombosis and Haemostasis
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab.
Yasser Khder, Serge Côté, Klaus Peter Hoffmann, Debra Freedholm, Dan Bloomfield, Jean M. Connors   +5 more
doaj   +1 more source

Impact of Stress‐Induced Hyperglycemia on In‐Hospital Medical Complications in Patients With Acute Stroke: From a Large‐Scale Nationwide Longitudinal Registry

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Aims This study aimed to explore the relationship between stress‐induced hyperglycemia (SIH) and in‐hospital medical complications in patients with acute stroke. Methods We enrolled 865,765 patients with acute stroke from the Chinese Stroke Center Alliance cohort.
Xintong Song, Yi Ju, Hongqiu Gu, Zhikai Zhu, Zixiao Li, Qian Zhang, Xingquan Zhao   +6 more
wiley   +1 more source

Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study

Frontiers in Pharmacology
BackgroundThe optimal anticoagulant administration for deep vein thrombosis (DVT) prevention following total joint arthroplasty (TJA) remains controversial.
Yinghao Wang, Yinghao Wang, Zhixin Liao, Zhixin Liao, Zongke Zhou, Zongke Zhou, Haoyang Wang, Haoyang Wang   +7 more
doaj   +1 more source

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundWe studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). Methods and ResultsENGAGE AF‐TIMI 48 was a randomized trial that compared 2
Haiyan Xu, Christian T. Ruff, Robert P. Giugliano, Sabina A. Murphy, Francesco Nordio, Indravadan Patel, Minggao Shi, Michele Mercuri, Elliott M. Antman, Eugene Braunwald   +9 more
doaj   +1 more source

Investigation on the incidence of adverse reactions of subcutaneous anticoagulant injection and its influencing factors (抗凝剂皮下注射不良反应发生率现况调查及其影响因素研究)

中西医结合护理, 2021
Objective To investigate the incidence and influencing factors of adverse reactions of injection site after subcutaneous anticoagulant injection under the guidance of evidence-based nursingMethods Using the convenient sampling method, 608 patients with ...
DAI Lili (代莉莉), DUAN Yanqin (段艳芹), ZHANG Mei (张梅), ZHU Suqin (朱素芹), CHEN Juan (陈娟), SUN Yuling (孙玉玲)   +5 more
doaj   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Danaparoid—Consensus Recommendations on Its Clinical Use

Pharmaceuticals
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis.
Rupert M. Bauersachs, Edelgard Lindhoff-Last, Robert Klamroth, Andreas Koster, Marc Schindewolf, Harry Magnani   +5 more
doaj   +1 more source

Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI

Медицинский совет, 2019
This article is devoted to the problem of combined antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS).
A. D. Erlich
doaj   +1 more source

Comparison of Novel Oral Anticoagulants and Vitamin K Antagonists in Patients With Cerebral Venous Sinus Thrombosis on Efficacy and Safety: A Systematic Review

Frontiers in Neurology, 2020
Vitamin K antagonists (VKAs) are guideline-suggested subacute anticoagulants for cerebral venous sinus thrombosis (CVST), although there is potential hemorrhage risk in clinical use. In the last decade, novel oral anticoagulants (NOACs) have been applied
Hongjie Li, Meiling Yao, Songjie Liao, Jingyan Chen, Jian Yu   +4 more
doaj   +1 more source